Dental Care Clinics in Fernley, NV Accepting Medicare
5 Dental Care Clinics found. Showing 1 - 5
 Desert Valley Dental Dentist Medicare: Not Enrolled in Medicare Practice Location: 300 Hwy 95 A So, Suite 110 Bldg A, Fernley, NV 89408 Phone: 775-575-0777 Fax: 775-575-1336 |
Salar And Delisle Llc Dentist Medicare: Not Enrolled in Medicare Practice Location: 1420 Us Highway 95a N Ste 2, Fernley, NV 89408 Phone: 425-306-2579 |
D'ascoli Orthodontics Dentist - Orthodontics and Dentofacial Orthopedics Medicare: Not Enrolled in Medicare Practice Location: 1420 Us Highway 95a N, Suite 2, Fernley, NV 89408 Phone: 775-782-3788 Fax: 775-882-1125 |
The Dentists' Office Fernley Llc Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 90 Falcon Dr Ste 110, Fernley, NV 89408 Phone: 775-336-1510 |
Steven Delisle Dds P.c. Dentist Medicare: Not Enrolled in Medicare Practice Location: 1420 Us Highway 95a N, Fernley, NV 89408 Phone: 425-306-2579 |
News Archive
Research opens up new ways to detect, inhibit cancer spread
Clusters of circulating cells commonly found in the blood of cancer patients have long been the subject of research on cancer. These clusters have been regarded for more than 50 years as malignant cells that have broken off from the primary tumor, spreading cancer to other parts of the body.
No overall survival benefit for bevacizumab in ovarian cancer
Addition of bevacizumab to first-line platinum-based chemotherapy does not improve overall survival in women with ovarian cancer, according to the mature data of the ICON7 trial.
Marshfield Clinic improves quality of health care and decreases Medicare costs
When the Centers for Medicare & Medicaid Services (CMS) initiated its Physician Group Practice (PGP) Demonstration, it challenged the 10 participating large physician group practices to prove that providing high quality coordinated health care could also save money.
Enrollment complete in Idera's IMO-3100 Phase 2 trial for psoriasis
Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.
FDA clears Mitsubishi's PATHFAST cardiac Troponin I diagnostic test
Mitsubishi Chemical Medience Corporation announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) premarketing notification clearance to the PATHFAST cTnI-II diagnostic test, clearing the way for its sale in the United States.
› Verified 8 days ago